Patient Monitoring & Vital Signs in Massachusetts

FIGUR8, Inc. develops FDA-registered musculoskeletal (MSK) assessment technology that replaces subjective measurement tools with objective, lab-grade biomechanics data. The company's flagship platform, the bioMotion Assessment Platform (bMAP), combines on-body wearable sensors with cloud-based analytics to provide precise movement analysis and functional capacity assessments. FIGUR8 serves physical therapists, orthopedic surgeons, chiropractors, occupational health clinics, workers' compensation payers, and sports medicine practitioners. The platform captures over one million data points during dynamic functional movement testing, offering quantitative metrics for injury assessment, recovery monitoring, and return-to-work determination. Use cases include workers' compensation claim management, surgical candidacy evaluation, post-injury rehabilitation tracking, and athletic performance assessment. FIGUR8 is particularly positioned for workers' compensation and occupational health markets, where objective MSK data reduces claim duration and improves outcomes. The company emphasizes clinical training and provider enablement through didactic courses and onsite support. Regulatory status includes FDA registration; the site references compliance with clinical standards and the APTA Digital Transparency Pledge. The technology addresses a significant clinical gap by providing consistent, repeatable objective metrics superior to manual muscle testing and traditional subjective clinical assessments.

Tekscan, Inc. designs and manufactures patented force measurement, pressure mapping, and tactile sensing solutions for clinical, research, and industrial applications. The company specializes in real-time pressure and temperature visualization systems used to measure and analyze force distribution between or across surfaces. Core product lines include pressure mapping systems for clinical assessment and R&D optimization, embedded flexible force sensors (FlexiForce) engineered for OEM device integration, and temperature mapping systems that correlate thermal and pressure data. A key clinical product is T-Scan Novus, a digital occlusal analysis system for dental applications that evaluates bite force, occlusion, and timing. Tekscan's solutions serve biomechanics research, dental diagnostics, orthopedic assessment, rehabilitation evaluation, automotive and manufacturing quality control, battery optimization, and electronics/semiconductor process validation. The company provides custom sensor design, rapid prototyping, and engineering consultation through TactileLab. Products are used by clinicians to improve patient outcomes and by engineers in R&D and quality control to validate designs and ensure repeatable performance. Tekscan was acquired by Uneo, Inc. in November 2025 and operates as part of the Tekscan Group. The company maintains technical support services, product training, and calibration capabilities.

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.

WatchRx is a digital healthcare platform built around smartwatch-enabled remote patient monitoring (RPM), chronic care management (CCM), transitional care management (TCM), and medication adherence solutions. The company provides an AI/ML-enabled cloud platform that integrates wearable technology to collect real-time patient vital signs and behavioral data, enabling clinicians to deliver proactive, value-based care and improve patient outcomes while reducing hospitalizations and urgent care visits. Primary markets include independent practices and primary care clinics, hospital systems, accountable care organizations (ACOs), and senior living and home care facilities. The platform automates clinical workflows, generates actionable insights for physicians, and supports medication adherence monitoring and GPS tracking for senior populations. Clinical evidence cited on the site demonstrates 76% reduction in hospitalizations, 51% reduction in urgent visits, and 90% patient satisfaction. The solution generates approximately $220+ additional revenue per patient per month through RPM/CCM billing codes. WatchRx partners with major healthcare networks and UnitedHealth Group. The company serves the growing market of value-based care delivery and remote monitoring, targeting reduction of healthcare costs and physician burnout while improving care coordination and patient engagement.

BioSensics is a wearable sensor and digital health technology company founded in 2007 by three Harvard University scientists. The company specializes in developing FDA-registered medical devices and digital biomarkers for clinical trials, remote patient monitoring, and health assessments, particularly for older adults and neurological disorders. BioSensics' core offerings include advanced fall detection and prevention systems with automatic fall alert capabilities, continuous monitoring of fall risk and physical activity, balance and gait assessment technologies, and cognitive function monitoring sensors. The company also provides the BioDigit Home platform, a centralized data aggregation system that integrates data from various digital health technologies. BioSensics has licensed its fall detection technology to major retailers and medical device manufacturers and provides comprehensive operational and technical services for clinical research across therapeutic areas including Alzheimer's disease, Parkinson's disease, and stroke. With over $50 million in NIH funding support, BioSensics has established itself as a leader in objective measurement of disease symptoms and validated biomarkers for clinical and research applications.

AION Biosystems develops and commercializes the AION TempShield™, an FDA-cleared Class II medical device for continuous, non-invasive body temperature monitoring. The TempShield is a wearable sensor designed for 24/7 real-time tracking with up to 90 days of battery life per charge. The device features Bluetooth connectivity, mobile app integration, and seamless electronic medical record (EMR) integration, supported by a dedicated clinician dashboard. Reimbursable under CMS code 99454, the TempShield targets early detection of infection-related complications across multiple clinical settings: oncology (60% of cancer deaths are infection-related), post-operative care (23.7% of surgical patients experience postoperative fever), pediatrics (75,000 children develop sepsis annually in the U.S.), long-term care facilities, and general sepsis management. The device addresses a critical care gap by enabling earlier identification of infection before progression to severe sepsis or organ failure, potentially reducing hospitalizations, readmissions, and associated healthcare costs. Clinical evidence cited on the company website demonstrates that each hour of delay in antibiotic administration for sepsis increases mortality risk by 7.6%, making early detection instrumental to patient outcomes. Manufacturing and regulatory capabilities include FDA 510(k) clearance and integration with major health information systems.

SEKISUI Diagnostics is a global leader in diagnostic reagents, biochemistry products, and point-of-care testing solutions with over 40 years of industry experience. The company manufactures and supplies clinical chemistry reagents, performing over 1.8 billion tests annually worldwide. Core product lines include Clinical Chemistry reagents for laboratory analyzers, Point-of-Care Testing (POCT) solutions in multiple formats to enable rapid diagnosis in office and clinic settings, and specialty biochemical enzymes for diagnostic reagent and biosensor manufacturers. SEKISUI also provides Blood Collection Tube Raw Materials and pre-analytic systems for plasma collection tubes, serving blood collection manufacturers globally. The Metrix® COVID/Flu Test represents their molecular diagnostics portfolio, offering point-of-care detection and differentiation of SARS-CoV-2, Flu A, and Flu B with small footprint and streamlined workflow. Beyond products, SEKISUI offers Biopharma Services supporting biotherapeutic and pharmaceutical manufacturing, technical transfer, and process scale-up. The company serves core laboratories, healthcare providers, in vitro diagnostics manufacturers, and distributors. SEKISUI combines analytical accuracy with operational efficiency, positioning products for cost containment and outcome improvement across clinical settings. The organization emphasizes patient-centric diagnostic solutions and maintains comprehensive technical and educational support for laboratory and clinical professionals.